Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   151 Trials   151 Trials   7120 News 


«12...1213141516171819202122...8687»
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Observational data, Retrospective data, Journal, Adherence:  Investigating the impact of a national educational program on patient adherence to osteoporosis medications. (Pubmed Central) -  Jul 9, 2023   
    However, some patients had a period of treatment discontinuation, placing them at increased risk of fracture. A focused program emphasizing the importance of long-term adherence with denosumab (including switching to bisphosphonates if treatment is discontinued) may be warranted to further improve the quality use of osteoporosis treatment in Australia.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal, Adherence:  Impact of the COVID-19 Pandemic on Adherence to Denosumab Therapy: A Single Center Study. (Pubmed Central) -  Jul 6, 2023   
    Denosumab adherence remained constant but postponed cases significantly increased during the COVID-19 pandemic. Better communication by health providers on denosumab adherence and alternative administration may reduce dosing interruptions in similar pandemic situations.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Paraneoplastic eosinophilic fasciitis associated with metastatic breast cancer () -  Jul 3, 2023 - Abstract #WCD2023WCD_5994;    
    This study revealed that 2 years of denosumab treatment in female RA patients achieved comparable efficacy on BMD to controls at the lumbar spine, but showed somewhat insufficient improvement at the femur neck and total hip. The patient
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Denosumab Attenuates Glucolipotoxicity-Induced ?-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals. (Pubmed Central) -  Jul 2, 2023   
    Furthermore, the increase in inflammatory cytokines and ROS caused by the RANK/RANKL signal also played an important role in glucolipotoxicity-induced cytotoxicity, and DMB can also protect ?-cells by reducing the mechanisms mentioned above. These findings provide detailed molecular mechanisms for the future development of DMB as a potential protective agent of ?-cells.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Retrospective data, Journal:  Denosumab-associated jaw bone necrosis in cancer patients: retrospective descriptive case series study. (Pubmed Central) -  Jun 30, 2023   
    Conservative surgery, along with antibiotic therapy and discontinuation of DMB, was found to be effective in managing the condition. Additional studies are needed to investigate the contribution of steroids and anticancer drugs to jaw bone necrosis, the prevalence of multicenter cases, and whether there is any drug interaction with DMB.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Potential alternative drug treatment for bone giant cell tumor. (Pubmed Central) -  Jun 29, 2023   
    The 7 genes (including ANGPT2, COL1A1, COL1A2, CTSK, FGFR1, NTRK2, and PDGFB) and 17 drugs, which have not been used in BGCT, but 6 of them approved by the FDA for other diseases, could be potential genes and drugs, respectively, to improve BGCT treatment. In addition, the correlation study and analysis of potential drugs through genes provide great opportunities to promote the repositioning of drugs and the study of pharmacology in the pharmaceutical industry.
  • ||||||||||  Journal:  Medication safety in chronic kidney disease. (Pubmed Central) -  Jun 29, 2023   
    Several medications increase the risk of development of acute kidney injury or progression of CKD. Close attention is needed to select the appropriate dose or safer alternatives to reduce the risk of drug-induced harm in patients with CKD.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Bones of contention: Predicting and preventing fractures in patients receiving peritoneal dialysis. (Pubmed Central) -  Jun 26, 2023   
    Denosumab is more commonly used and has some evidence for improvement in BMD but carries with it a high risk of hypocalcaemia requiring rigorous prophylaxis. More research is needed to explore practical methods to identify those at risk of fracture and determine the efficacy of antiresorptive and anabolic therapies to decrease this risk.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  An improved total en bloc spondylectomy for L5 vertebral giant cell tumor through a single-stage posterior approach. (Pubmed Central) -  Jun 26, 2023   
    Single-stage posterior TES for L5 GCT was previously considered impossible. In this study, we presented our experience with the use of an improved surgical technique for L5 TES through the single-stage posterior approach, which has proved to be superior to the conventional procedures in terms of blood loss control and complication and recurrence rates.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Retrospective data, Journal:  Treatment outcomes and time to healing of medication-related osteonecrosis of the jaw based on image findings. (Pubmed Central) -  Jun 26, 2023   
    The image findings on the internal texture of the lesions at the initial examination and chemotherapy were associated with the treatment outcomes of nonoperative management of MRONJ. The image findings of "Sequestrum formation" were associated with lesions taking a short time to heal and better outcomes, whereas "Sclerosis" and "Normal" were associated with lesions with longer healing times.
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion:  A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis (clinicaltrials.gov) -  Jun 22, 2023   
    P3,  N=332, Completed, 
    The image findings of "Sequestrum formation" were associated with lesions taking a short time to heal and better outcomes, whereas "Sclerosis" and "Normal" were associated with lesions with longer healing times. Active, not recruiting --> Completed
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Review, Journal:  Pharmacological Interventions for Glucocorticoid-Induced Osteoporosis: An Umbrella Review. (Pubmed Central) -  Jun 20, 2023   
    Moderate- to high-level evidence suggests that teriparatide, bisphosphonates, and denosumab can improve the bone mineral density in patients with GIOP. The findings of this umbrella review can enable patients and clinical healthcare professionals to choose the best drug prescription.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Retrospective data, Journal:  Computed tomography density changes of bone metastases after concomitant denosumab. (Pubmed Central) -  Jun 19, 2023   
    We have found that long-term treatment with DM increases bone density progressively in oncologic patients. This effect can be observed not only at the level of secondary lesions but also at the level of apparently normal trabecular bone and is more pronounced for osteolytic metastases.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  The efficacy and safety of short-course neoadjuvant denosumab for en bloc spondylectomy in spinal giant cell tumor of bone: a preliminary report. (Pubmed Central) -  Jun 16, 2023   
    Denosumab and alendronate showed comparable efficacy in improving BMD at all measured skeletal sites and were safe and well-tolerated, with no serious adverse effects reported in RTRs with low bone mass. Short-term neoadjuvant denosumab could yield radiological and histological responses and might facilitate en bloc spondylectomy by hardening the tumor and causing less adhesion to segmental vessels, major vessels and nerve roots, which was beneficial to achieve the optimal oncological and functional outcomes.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Drug-induced osteopetrosis. (Pubmed Central) -  Jun 16, 2023   
    Additionally, however, in 2003 we published a case report demonstrating that prolonged excessive dosing during childhood of the antiresorptive aminobisphosphonate pamidronate can sufficiently block osteoclast and chondroclast activity to recapitulate the skeletal features of OPT. Herein, we include further evidence of drug-induced OPT by illustrating osteopetrotic skeletal changes from repeated administration of high doses of the aminobisphosphonate zoledronic acid (zoledronate) given to children with osteogenesis imperfecta.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Preclinical, Journal:  RANKL Inhibition Reduces Cardiac Hypertrophy in mdx Mice and Possibly in Children with Duchenne Muscular Dystrophy. (Pubmed Central) -  Jun 14, 2023   
    Interestingly, preliminary post hoc analyses suggest that denosumab, a human anti-RANKL, reduced left ventricular hypertrophy in two patients with DMD. Taken together, our results indicate that anti-RANKL treatment prevents the worsening of cardiac hypertrophy in mdx mice and could potentially maintain cardiac function in teenage or adult patients with DMD.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Retrospective data, Journal:  A retrospective analysis of nonresponse to denosumab after hip fractures. (Pubmed Central) -  Jun 13, 2023   
    The results of our study highlight the importance of timely denosumab administration when using this drug for osteoporosis management. Physicians should keep these results in mind in clinical practice so that they can improve utilization of 6-month denosumab.
  • ||||||||||  MB09 (denosumab biosimilar) / Grupo Insud, Amneal, Korea Kolmar
    Trial completion:  A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva (clinicaltrials.gov) -  Jun 13, 2023   
    P1,  N=255, Completed, 
    Physicians should keep these results in mind in clinical practice so that they can improve utilization of 6-month denosumab. Active, not recruiting --> Completed
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Trial completion, Trial completion date:  Denosumab and Male Infertility: a RCT (clinicaltrials.gov) -  Jun 13, 2023   
    P2,  N=95, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Oct 2021 --> May 2023
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Preserving the oral health of patients on antiresorptive drugs (Pubmed Central) -  Jun 12, 2023   
    However, bisphosphonates and denosumab may, in rare cases, induce osteonecrosis of the jaw, especially when prescribed for malignant disease (bone metastases or multiple myeloma)...An oral check-up and oral cavity restoration are strongly recommended before treatment, as well as the implementation of rigorous oral hygiene and regular visits to the dental surgeon. During and after treatment with antiresorptive medication, oral care protocols are used to reduce the risk of osteonecrosis of the jaws and, when it occurs, to manage it.